Astellas Pharma Inc. (ALPMY)
OTCMKTS
· Delayed Price · Currency is USD
10.07
+0.50 (5.22%)
Apr 25, 2025, 4:00 PM EDT
Astellas Pharma Revenue
In the fiscal year ending March 31, 2025, Astellas Pharma had annual revenue of 1.91T JPY with 19.25% growth. Astellas Pharma had revenue of 459.29B in the quarter ending March 31, 2025, with 10.78% growth.
Revenue
1,912.32B JPY
Revenue Growth
+19.25%
P/S Ratio
1.40
Revenue / Employee
129.61M JPY
Employees
14,754
Market Cap
17.84B USD
Revenue Chart
* This company reports financials in JPY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 1,912.32B | 308.65B | 19.25% |
Mar 31, 2024 | 1,603.67B | 85.05B | 5.60% |
Mar 31, 2023 | 1,518.62B | 222.46B | 17.16% |
Mar 31, 2022 | 1,296.16B | 46.64B | 3.73% |
Mar 31, 2021 | 1,249.53B | -51.32B | -3.94% |
Mar 31, 2020 | Pro | Pro | Pro |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo Inc. | 1.76B |
Veradigm | 588.02M |
Glass House Brands | 200.90M |
Northwest Biotherapeutics | 1.38M |
Elite Pharmaceuticals | 70.00M |
BioStem Technologies | 301.83M |
American Oncology Network | 1.76B |
Silence Therapeutics | 43.26M |
Astellas Pharma News
- 2 days ago - Astellas Pharma reports FY results - Seeking Alpha
- 10 days ago - Zydus Lifesciences confirms losing US patent case to Astellas in mirabegron litigation - Business Upturn
- 12 days ago - Zydus down 5%, Lupin down nearly 4% as US court orders withdrawal of Myrbetriq drug - Business Upturn
- 4 weeks ago - Singlera Genomics Presented Non-Invasive Testicular Toxicity Detection with Astellas at 2025 SOT Meeting - GlobeNewsWire
- 6 weeks ago - Astellas Pharma: Raising New, As Yet Unanswered Questions In Stomach Cancer And Moving Their Pipeline Forward - Seeking Alpha
- 7 weeks ago - Astellas and YASKAWA Agree to Establish a Joint Venture Focused on Cell Therapy Manufacturing - PRNewsWire
- 2 months ago - Astellas and MBC BioLabs Announce the Sixth Annual Astellas Future Innovator Prize - PRNewsWire
- 2 months ago - U.S. FDA Approves Expanded Label for Astellas' IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy - PRNewsWire